The White House (WH) issued three executive orders (EO) Friday, July 24. A fourth is being held pending a meeting with drug company executives set for tomorrow, Tuesday, July 28.
While all are important, the Advocacy Council believes this fourth EO is the one that will most directly affect allergy. It was not released, pending a meeting tomorrow with pharma executives to discuss ways to lower drug prices. The Advocacy Council will provide details of the results of this meeting when they become available.
According to statements from the WH, the pending EO seeks to ensure "… that the United States pays the lowest price available in economically comparable countries for Medicare Part B drugs.” The WH also stated that the United States often pays 80% more for these drugs than other developed countries. "Absent successful negotiations with drug company executives, this Order will be implemented on August 24."
Briefly, the first EO relates to insulin and epinephrine. This EO is exclusive to the cost and savings achieved through Federally Qualified Health Centers (FQHCs) and ensures savings are passed along to the patient and government and not retained by the FQHC. We are not certain how many of our patients this will help.
The second EO is about drug importation and re-importation of drugs.
The third EO deals with Pharmacy Benefit Managers and passing along the savings to the patient.
Some media outlets are reporting that these moves are largely symbolic as regulatory and other actions would be needed to implement key features of the Executive Orders.
The Advocacy Council will monitor the meeting tomorrow with pharma and provide more details later this week. The Advocacy Council – we have you covered.